Home/ Stocks/ ARQT

Arcutis Biotherapeutics, Inc. Common Stock

ARQT XNAS

$25.29 -1.12 (-4.24%) ▼ 15-min delayed

Open

$26.65

High

$26.88

Low

$25.27

Volume

2.45M

Market Cap

$3.32B

About Arcutis Biotherapeutics, Inc. Common Stock

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 354 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$129.86M	$15.01M	$0.11
Q1 2026	$105.40M	$-11,295,000	$-0.09
FY 2025	$376.07M	$-16,141,000	$-0.13
Q3 2025	$99.22M	$7.41M	$0.06

Related Market News

No specific coverage for ARQT yet. Check out our latest market news or earnings calendar.

Get ARQT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Arcutis Biotherapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.